Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 1;19(4):255–264. doi: 10.1089/dia.2016.0405

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Allen B. King et al., 2017; Published by Mary Ann Liebert, Inc.

This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

PMC Copyright notice

FIG. 1. — Nine-point SMBG^† profile^‡ showing calculation of range (a) and change from baseline to EOT in DUAL I and DUAL II (b). ^†SMBG assessed with glucose meter as plasma equivalent values of capillary whole blood glucose. ^‡Illustrative example not intended to represent actual patients or treatment effects. Data are based on FAS, with LOCF for all subjects with a full nine-point profile at baseline; P-values are from ANCOVA with treatment, region, baseline HbA_1c stratum (≤8.3% [≤67 mmol/mol], >8.3% [>67 mmol/mol]), and previous OAD treatment as fixed effects, and baseline value of the parameter included as covariate. ANCOVA, analysis of covariance; EOT, end-of-trial; ETD, estimated treatment difference; FAS, full analysis set; HbA_1c, glycosylated hemoglobin; IDeg, insulin degludec; IDegLira, fixed ratio combination of insulin degludec and liraglutide; Lira, liraglutide; LOCF, last observation carried forward; OAD, oral antidiabetic drug; NS, not significant; SMBG, self-monitored blood glucose.